A Deep-Dive into Efruxifermin as a therapy for nonalcoholic steatohepatitis

Executed on:Sep 21, 2022 10:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Arizona Liver Health (ALH)The VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.
Treats 1000 patients with NASH.
Fellowship trained (Adult Transplant Hepatology) at the Cleveland Clinic.
Specializes in nonalcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation; has over 160 publications and presents his work at both national and international medical conferences. 

Interview Goal

This conversation will focus on the NASH treatment landscape with a focus on the recent data from Akero's HARMONY Phase IIb trial for efruxifermin.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.